AU2003288739A1 - Use of carnitines for the prevention and/or treatment of disorders caused by the andropause - Google Patents

Use of carnitines for the prevention and/or treatment of disorders caused by the andropause

Info

Publication number
AU2003288739A1
AU2003288739A1 AU2003288739A AU2003288739A AU2003288739A1 AU 2003288739 A1 AU2003288739 A1 AU 2003288739A1 AU 2003288739 A AU2003288739 A AU 2003288739A AU 2003288739 A AU2003288739 A AU 2003288739A AU 2003288739 A1 AU2003288739 A1 AU 2003288739A1
Authority
AU
Australia
Prior art keywords
prevention
treatment
andropause
carnitines
disorders caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003288739A
Other languages
English (en)
Inventor
Giulio Biagiotti
Giorgio Cavallini
Aleardo Koverech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of AU2003288739A1 publication Critical patent/AU2003288739A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003288739A 2002-12-13 2003-11-20 Use of carnitines for the prevention and/or treatment of disorders caused by the andropause Abandoned AU2003288739A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM2002A000620 2002-12-13
IT000620A ITRM20020620A1 (it) 2002-12-13 2002-12-13 Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
PCT/IT2003/000757 WO2004054567A1 (en) 2002-12-13 2003-11-20 Use of carnitines for the prevention and/or treatment of disorders caused by the andropause

Publications (1)

Publication Number Publication Date
AU2003288739A1 true AU2003288739A1 (en) 2004-07-09

Family

ID=32587900

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003288739A Abandoned AU2003288739A1 (en) 2002-12-13 2003-11-20 Use of carnitines for the prevention and/or treatment of disorders caused by the andropause

Country Status (17)

Country Link
US (1) US7956091B2 (enExample)
EP (1) EP1569635B1 (enExample)
JP (1) JP4767542B2 (enExample)
KR (1) KR101039818B1 (enExample)
AT (1) ATE422883T1 (enExample)
AU (1) AU2003288739A1 (enExample)
CA (1) CA2507429C (enExample)
CY (1) CY1109051T1 (enExample)
DE (1) DE60326262D1 (enExample)
DK (1) DK1569635T3 (enExample)
ES (1) ES2322455T3 (enExample)
IT (1) ITRM20020620A1 (enExample)
MX (1) MXPA05006072A (enExample)
PL (1) PL211032B1 (enExample)
PT (1) PT1569635E (enExample)
SI (1) SI1569635T1 (enExample)
WO (1) WO2004054567A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272812A1 (en) * 2002-02-07 2005-12-08 Pettegrew Jay W Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans
US7407778B2 (en) 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US7815894B2 (en) 2003-05-29 2010-10-19 Jay W. Pettegrew Compounds, compositions and methods for medical imaging of neuropsychiatric disorders
ITRM20040561A1 (it) 2004-11-11 2005-02-11 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile.
KR101460125B1 (ko) * 2013-02-05 2014-11-11 주식회사 바이오그랜드 루이보스 추출물을 유효성분으로 하는 남성 노화 및 갱년기 예방 및 개선용 조성물
WO2016167254A1 (ja) * 2015-04-17 2016-10-20 株式会社山田養蜂場本社 蜂の子を含有する滋養強壮剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3830931A (en) * 1972-11-06 1974-08-20 Felice S De Carnitine and its use in the treatment of arrhythmia and impaired cardiac function
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT1116037B (it) * 1979-04-23 1986-02-10 Sigma Tau Ind Farmaceuti Esteri e ammidi di acil carnitine loro procedimenti di preparazione e loro uso terapeutico
IT1157238B (it) * 1982-10-29 1987-02-11 Sigma Tau Ind Farmaceuti Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile
EP0681839A3 (en) * 1994-05-12 1997-11-12 Hirohiko Kuratsune A pharmaceutical preparation comprising an acylcarnitine
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
IT1295408B1 (it) * 1997-10-03 1999-05-12 Sigma Tau Ind Farmaceuti Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo
IT1302125B1 (it) * 1998-08-03 2000-07-31 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed antiproliferativacomprendente una carnitina ed un carotenoide
IT1302307B1 (it) * 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
IT1306130B1 (it) * 1999-04-16 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti.
US6399116B1 (en) * 2000-04-28 2002-06-04 Rulin Xiu Rhodiola and used thereof
ES2275881T3 (es) * 2001-05-29 2007-06-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Uso de un alcanoil l-carnitina para la preparacion de una medicacion para tratar anhedonia.

Also Published As

Publication number Publication date
EP1569635A1 (en) 2005-09-07
PL211032B1 (pl) 2012-04-30
DK1569635T3 (da) 2009-04-20
JP2006511531A (ja) 2006-04-06
KR101039818B1 (ko) 2011-06-09
SI1569635T1 (sl) 2009-06-30
DE60326262D1 (de) 2009-04-02
US20060135606A1 (en) 2006-06-22
CA2507429A1 (en) 2004-07-01
ATE422883T1 (de) 2009-03-15
EP1569635B1 (en) 2009-02-18
MXPA05006072A (es) 2005-09-30
US7956091B2 (en) 2011-06-07
ITRM20020620A1 (it) 2004-06-14
PL378418A1 (pl) 2006-04-03
CY1109051T1 (el) 2014-07-02
KR20050084052A (ko) 2005-08-26
ES2322455T3 (es) 2009-06-22
CA2507429C (en) 2012-09-04
JP4767542B2 (ja) 2011-09-07
WO2004054567A1 (en) 2004-07-01
PT1569635E (pt) 2009-05-11

Similar Documents

Publication Publication Date Title
WO2000011968A8 (en) ANTIOXIDANT COMPOSITION COMPRISING ACETYL L-CARNITINE AND α-LIPOIC ACID
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand
CY1109051T1 (el) Χρηση καρνιτινων για την προληψη και/ή θεραπεια διαταραχων που προκαλουνται απο την ανδροπαυση
AU2002303502A1 (en) Improved leads for the treatment of patients with chf
TW200744574A (en) Use of L-carnitine or of alkanoyl L-carnitines for the preparation of a physiological supplement of medicament for ophthalmic use in the form of eye-drops
CY1111273T1 (el) Συνδυασμενη χρηση της l-καρνιτινης, ακετυλο l-καρνιτινης και προπιονυλο l-καρνιτινης για τη θεραπεια της ολιγοασθενοτερατοσπερμιας
AR021172A1 (es) Composicion antiprolifica, antioxidante, que comprende una carnitina y un carotenoide
AU2003274703A1 (en) Use of propionyl l-carnitine for the preparation of a medicament for the treatment of glaucoma
WO2001007039A3 (en) L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases
SG162836A1 (en) Use of a combination comprising l-carnitine or alkanoyl l-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases
IL149619A0 (en) Composition for prevention and/or treatment of disorders due to abnormal lipid metabolism, comprising propionyl l-carnitine and chitosan
PL1824472T3 (pl) Zastosowanie acetylo-L-karnityny do wytwarzania leku do leczenia zespołu fibromialgii
WO2001064203A3 (en) Composition for the prevention and/or treatment of vascular diseases, comprising propionyl l-carnitine and coenzyme q¿10?
PL1937245T3 (pl) Związek użyteczny w zapobieganiu i leczeniu przerostu lewej komory u pacjentów dializowanych
IL164763A0 (en) Byperforin derivatives, the use thereof and formulations containing them
MXPA03010919A (es) Uso de acetil l-carnitina para preparacion de medicamento para terapia preventiva del dolor.
AU2002311141A1 (en) The use of hydrochloric acid in the preparation of a medicament for the treatment of tumour
TW200420560A (en) Crystalline form
MXPA03010920A (es) Uso de alconil l- carnitina para preparacion de medicamento para tratar anhedonia.
WO2008058993A3 (en) Use of alpha ketogluaric acid for the treatment of infection with h. pylori
RU2002124697A (ru) Биологически активная добавка "мумивит"
AU2002336725A1 (en) Use of methotrexate and l-arginine for the preparation of a medicament for treatment of uterine myoma
WO2002069956A3 (en) Use of carnitine for increasing testosteron
MX9304553A (es) Complejo de ibuprofen-beta-ciclodextrina para la fabricacion de unmedicamento de consumo oral, procedimiento para su preparacion ycomposiciones farmaceuticas que lo contienen.
AU2002221947A1 (en) Blocking the adsorption of germs in birds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase